Cancer, group of diseases involving abnormal cell growth, is one of the focuses of Tempus. Tempus is an organization or team with a shared goal: improve patient outcomes. They redefine how genomic data is used in a clinical setting. The organization’s goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. Eric Lefkofsky, Co-Founder and CEO, leads the Leadership Team of the company. He founded the company last 2015 after his successful stint of Groupon. Kevin White, PhD serves as the president while Gary Palmer, MD is the Chief Medical Officer.
Tempus provides unique sequencing services and analyzes somatic and germ line molecular data with the intended therapeutic data to allow physicians to make scientific data-based decisions. They use a new approach to next-generation sequencing. The physicians have access to a diversity of sequencing capabilities, all with full transcriptome and tumor/normal match. It makes the decisions easier. Tempus regularly partners with top leading physicians and tertiary hospitals to supplement a health institution’s current offering by providing access to genomic sequencing with breakthrough analytics and an interactive machine learning platform that also leverages data from biological models, proteomics and single cell genomics.
Samples are collected with proper consent. Tempus works directly with the physicians and the patients to gather appropriate samples for DNA and RNA sequencing. The Tempus Laboratory is a state-of-the-art building that brings data science and technology into clinical care. The CLIA-certified Tempus Lab is a highly robotic or automated laboratory optimized for high-throughput clinical next-generation sequencing services with a current capacity of over 50,000 patients every year. The usual timeline for sequencing is within two weeks to three weeks of receiving the patient samples.
Apart from sequencing, Tempus also pioneers on Breast Cancer research. One of the organization’s goals is to discover new “targeted” therapies that may selectively kill cancer cells while keeping healthy/normal cells intact.
Recently, Tempus partnered with University of Chicago Medicine to Collaborate on Pancreatic Cancer Research Project. Tempus works along with a leading team of scientists and physicians from the Chicago Pancreatic Cancer Initiative (CPCI), spearheaded by Ralph Weichselbaum, MD, who is the professor and chairman of the Department of Radiation Oncology at the University of Chicago.